Technical Analysis for INCY - Incyte Corporation

Grade Last Price % Change Price Change
F 78.66 0.27% 0.21
INCY closed up 0.27 percent on Friday, February 26, 2021, on 1.24 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical INCY trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Multiple of Ten Bearish Other 0.27%
Oversold Stochastic Weakness 0.27%
Slingshot Bearish Bearish Swing Setup -2.42%
Stochastic Buy Signal Bullish -2.42%
Multiple of Ten Bullish Other -2.42%
Oversold Stochastic Weakness -2.42%
Lizard Bullish Bullish Day Trade Setup -0.46%
Doji - Bullish? Reversal -0.46%
Older End-of-Day Signals for INCY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 19 hours ago
Up 1% about 19 hours ago
Trending on StockTwits 1 day ago
Down 3% 1 day ago
60 Minute Opening Range Breakdown 2 days ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Incyte Corporation Description

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. The company markets JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, a JAK inhibitor, which is in Phase III clinical trial for polycythemia vera; Phase II trial for essential thrombocythemia; Phase II trial for pancreatic cancer; Phase I/II trial to treat solid tumors/other hematologic malignancies, as well as baricitinib, a JAK inhibitor, which is Phase III trial for rheumatoid srthritis, Phase IIb trial for psoriasis, and Phase II trial for diabetic nephropathy. The company's products in pipeline also comprise INCB28060 and INCB24360, which are Phase II clinical trial products for the treatment of solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Solid Tumors Chemical Compounds Organic Compounds Inflammation Wilmington Psoriasis Pancreatic Cancer Hematologic Malignancies Janus Diabetic Nephropathy Clinical Trial Product Myelofibrosis Janus Kinase Inhibitor Clinical Trial Products Morpholines Nitriles Polycythemia

Is INCY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 110.365
52 Week Low 62.51
Average Volume 1,138,974
200-Day Moving Average 92.19
50-Day Moving Average 88.45
20-Day Moving Average 85.40
10-Day Moving Average 80.90
Average True Range 3.04
ADX 24.24
+DI 16.65
-DI 31.90
Chandelier Exit (Long, 3 ATRs ) 89.04
Chandelier Exit (Short, 3 ATRs ) 85.82
Upper Bollinger Band 95.57
Lower Bollinger Band 75.23
Percent B (%b) 0.17
BandWidth 23.82
MACD Line -3.20
MACD Signal Line -2.38
MACD Histogram -0.8185
Fundamentals Value
Market Cap 17.23 Billion
Num Shares 219 Million
EPS 1.87
Price-to-Earnings (P/E) Ratio 42.04
Price-to-Sales 7.58
Price-to-Book 7.82
PEG Ratio 0.85
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 81.47
Resistance 3 (R3) 81.48 80.56 81.00
Resistance 2 (R2) 80.56 79.85 80.55 80.84
Resistance 1 (R1) 79.61 79.40 79.15 79.60 80.69
Pivot Point 78.69 78.69 78.46 78.68 78.69
Support 1 (S1) 77.74 77.98 77.28 77.73 76.63
Support 2 (S2) 76.82 77.53 76.81 76.48
Support 3 (S3) 75.87 76.82 76.32
Support 4 (S4) 75.86